product name Flunixin Meglumin
Description: Flunixin Meglumin is a potent inhibitor of the enzyme cyclooxygenase used as analgesic agent with anti-inflammatory and antipyretic activity. Flunixin meglumine serves as a non-narcotic and non-steroidal analgesic agent with antipyretic activities. Moreover, Flunixin meglumine could be applied as a drug in animals for the management of intestinal ischaemia, colic, and endotoxemia.
References: J Pharmacol Exp Ther. 1977 Mar;200(3):501-7.
491.46
Formula
C14H11F3N2O2.C7H17NO5
CAS No.
42461-84-7
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 98 mg/mL (199.4 mM)
Water: 98 mg/mL (199.4 mM)
Ethanol: 8 mg/mL (16.3 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19408048
| In Vitro |
In vitro activity: An in vitro whole blood model in feedlot calves was adopted to detect the activity of the anti-inflammatory agents Flunixin-meglumine (FLU), RS (±) Carprofen (CPF) and S (+) CPF. The drugs all exhibited inhibitory activity on COXs, with an order of FLU > S (+) CPF > RS (±) CPF in their potency. This finding indicated that FLU was a nonselective suppressorr of bovine COXs, whereas RS (±) CPF and S (+) CPF selectively inhibited COX-2 isoenzyme. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Findings from mice, rats and monkeys suggested Flunixin meglumine as a potent non-narcotic analgesic agent after parenteral administration. After being subcutaneous administered, this agent showed higher efficacy than pentazocine, meperidine and codeine in the rat yeast paw test. Intramuscular administration and subcutaneous administration of Flunixin meglumine had similar effects. Moreover, orally administered Flunixin meglumine also exerted analgesic and anti-inflammatory activities. Based on mice abdominal constriction test, flunixin meglumine had comparable efficacy to pentazocine and was more potent than meperidine and codeine. In primates, 10 mg/kg flunixin meglumine showed an equal efficacy to that of 0.3 mg/kg morphine. |
| Animal model | |
| Formulation & Dosage | |
| References | J Vet Pharmacol Ther. 2014 Feb;37(1):43-52; J Pharmacol Exp Ther. 1977 Mar;200(3):501-7. |
